Clinical Trial

A Study of IBI363 in Subjects with Advanced Solid Malignancies

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 19, 2024 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-25; most recent amendment 2024-12-16.
Status change: Not Yet Recruiting → Recruiting 2024-06-07
Trial Details
NCT Number NCT06281678
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
Enrollment 178 participants
Start Date 2024-04-08
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-19